Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Mass; Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass; Division of Cardiac, Thoracic, and Vascular Surgery, New York-Presbyterian/Columbia University Irving Medical Center, Columbia University Vagelos College of Physicians & Surgeons, New York, NY.
Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Mass; Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins Hospital, Baltimore, Md.
J Vasc Surg. 2021 Apr;73(4):1253-1260. doi: 10.1016/j.jvs.2020.08.033. Epub 2020 Sep 1.
Access issues are one of the most common complications of endovascular aneurysm repair (EVAR). However, contemporary rates as well as risk factors for complications and the subsequent impact of access complications on mortality are poorly described.
We studied all EVAR for intact abdominal aortic aneurysms without prior aortic surgery in the Vascular Quality Initiative between 2011 and 2018. We studied factors associated with access complications (thrombosis, embolus, wound infection, hematoma, and conversion to cutdown), as well as the interaction with female sex and the impact on survival using multilevel logistic regression and propensity weighting. Multiple imputation was used for missing data.
There were 33,951 EVAR during the study period (91% elective, 9% symptomatic); most cases (70%) involved an attempt at percutaneous access on at least one side, with 30% bilateral cutdowns and 0.1% iliac conduits. There were 1553 patients (4.6%) who experienced at least one access complication. Access complications were almost twice as common in female patients (7.5% vs 3.9%; P < .001). The factors associated with access complications included female sex (odds ratio [OR], 2.7; 95% confidence interval [CI], 2.0-3.6; P < .001), age (OR, 1.05 per 5 years; 95% CI, 1.02-1.1; P < .01), aortouni-iliac device (OR, 1.6; 95% CI, 1.1-2.3; P < .01), smoking (OR, 1.4; 95% CI, 1.1-1.7; P < .01), body mass index of less than 16 (OR, 1.8; 95% CI, 1.3-2.5; P = .001), dual antiplatelet therapy (1.3; 95% CI, 1.02-1.6 P = .03), prior infrainguinal bypass (OR, 1.8; 95% CI, 1.3-2.7; P < .01), and beta blocker use (OR, 1.2; 95% CI, 1.03-1.4; P = .02). Conversion from percutaneous access to open cutdown was associated with higher rates of complications than planned open cutdown (8.6% vs 2.9%; P < .001). In propensity-weighted analysis, percutaneous access was associated with significantly lower odds of access complications in women (OR, 0.6; 95% CI, 0.4-0.96; P = .03). Patients who experienced an access complication had more than four times the odds of perioperative death (OR, 4.2; 95% CI, 2.5-7.1; P < .001), and a 60% higher risk of long-term mortality (hazard ratio, 1.6; 95% CI, 1.2-2.1; P = .001). In addition to death, patients with access site complications had higher rates of other major complications, including reoperation during the index hospitalization (19% vs 1.2%; P < .001), myocardial infarction (3.5% vs 0.7%; P < .001), stroke (0.8% vs 0.2%; P < .001), acute kidney injury (12% vs 3%; P < .001), and reintubation (5.7% vs 0.8%).
Although access complications are infrequent in the current era, they are associated with both perioperative and long-term morbidity and mortality. Female patients in particular are at high risk of access complications, but may benefit from percutaneous access.
血管腔内动脉瘤修复术(EVAR)的最常见并发症之一是通路问题。然而,目前并发症的发生率以及危险因素,以及随后的通路并发症对死亡率的影响,都描述得很差。
我们研究了 2011 年至 2018 年期间血管质量倡议中所有未经主动脉手术的完整腹主动脉瘤的 EVAR。我们研究了与通路并发症(血栓形成、栓塞、伤口感染、血肿和转为切开术)相关的因素,以及女性性别与这些并发症的相互作用,以及使用多级逻辑回归和倾向评分加权对生存率的影响。使用多重插补法处理缺失数据。
研究期间共进行了 33951 例 EVAR(91%为择期手术,9%为症状性);大多数病例(70%)至少在一侧尝试了经皮入路,其中 30%为双侧切开术,0.1%为髂骨导管。有 1553 名患者(4.6%)至少经历了一次通路并发症。女性患者的通路并发症几乎是男性的两倍(7.5%比 3.9%;P<0.001)。与通路并发症相关的因素包括女性性别(比值比[OR],2.7;95%置信区间[CI],2.0-3.6;P<0.001)、年龄(每增加 5 岁 OR 增加 1.05;95%CI,1.02-1.1;P<0.01)、腹主动脉-髂动脉装置(OR,1.6;95%CI,1.1-2.3;P<0.01)、吸烟(OR,1.4;95%CI,1.1-1.7;P<0.01)、体重指数低于 16(OR,1.8;95%CI,1.3-2.5;P=0.001)、双联抗血小板治疗(1.3;95%CI,1.02-1.6;P=0.03)、先前的下肢旁路术(OR,1.8;95%CI,1.3-2.7;P<0.01)和β受体阻滞剂的使用(OR,1.2;95%CI,1.03-1.4;P=0.02)。从经皮入路转为开放切开术与计划的开放切开术相比,并发症发生率更高(8.6%比 2.9%;P<0.001)。在倾向评分加权分析中,女性经皮入路与通路并发症的几率显著降低(OR,0.6;95%CI,0.4-0.96;P=0.03)。经历过通路并发症的患者在围手术期死亡的几率是其他患者的四倍以上(OR,4.2;95%CI,2.5-7.1;P<0.001),长期死亡率的风险增加 60%(风险比,1.6;95%CI,1.2-2.1;P=0.001)。除了死亡,有通路部位并发症的患者其他主要并发症的发生率也较高,包括住院期间再次手术(19%比 1.2%;P<0.001)、心肌梗死(3.5%比 0.7%;P<0.001)、中风(0.8%比 0.2%;P<0.001)、急性肾损伤(12%比 3%;P<0.001)和再插管(5.7%比 0.8%)。
尽管目前通路并发症并不常见,但它们与围手术期和长期的发病率和死亡率都有联系。特别是女性患者,通路并发症的风险很高,但可能受益于经皮入路。